Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Alx Oncology Holdings (ALXO) EBT Margin (2019 - 2023)

Alx Oncology Holdings' EBT Margin history spans 4 years, with the latest figure at 21943.61% for Q4 2023.

  • For Q4 2023, EBT Margin fell 3520898.0% year-over-year to 21943.61%; the TTM value through Dec 2023 reached 1577.32%, down 5026974.0%, while the annual FY2025 figure was 31.02%, 776828.0% down from the prior year.
  • EBT Margin for Q4 2023 was 21943.61% at Alx Oncology Holdings, down from 13040.66% in the prior quarter.
  • Across five years, EBT Margin topped out at 1765650.0% in Q3 2022 and bottomed at 21943.61% in Q4 2023.
  • The 4-year median for EBT Margin is 9269.62% (2023), against an average of 386103.27%.
  • The largest YoY upside for EBT Margin was -3520898bps in 2023 against a maximum downside of -175260934bps in 2023.
  • A 4-year view of EBT Margin shows it stood at 241.72% in 2019, then tumbled by -788bps to 2146.3% in 2020, then soared by 718bps to 13265.37% in 2022, then plummeted by -265bps to 21943.61% in 2023.
  • Per Business Quant, the three most recent readings for ALXO's EBT Margin are 21943.61% (Q4 2023), 13040.66% (Q3 2023), and 9269.62% (Q2 2023).